Literature DB >> 27377044

Viral and Synthetic RNA Vector Technologies and Applications.

Juliane W Schott1,2, Michael Morgan1,2, Melanie Galla1,2, Axel Schambach1,2,3.   

Abstract

Use of RNA is an increasingly popular method to transiently deliver genetic information for cell manipulation in basic research and clinical therapy. In these settings, viral and nonviral RNA platforms are employed for delivery of small interfering RNA and protein-coding mRNA. Technological advances allowing RNA modification for increased stability, improved translation and reduced immunogenicity have led to increased use of nonviral synthetic RNA, which is delivered in naked form or upon formulation. Alternatively, highly efficient viral entry pathways are exploited to transfer genes of interest as RNA incorporated into viral particles. Current viral RNA transfer technologies are derived from Retroviruses, nonsegmented negative-strand RNA viruses or positive-stranded Alpha- and Flaviviruses. In retroviral particles, the genes of interest can either be incorporated directly into the viral RNA genome or as nonviral RNA. Nonsegmented negative-strand virus-, Alpha- and Flavivirus-derived vectors support prolonged expression windows through replication of viral RNA encoding genes of interest. Mixed technologies combining viral and nonviral components are also available. RNA transfer is ideal for all settings that do not require permanent transgene expression and excludes potentially detrimental DNA integration into the target cell genome. Thus, RNA-based technologies are successfully applied for reprogramming, transdifferentiation, gene editing, vaccination, tumor therapy, and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27377044      PMCID: PMC5113109          DOI: 10.1038/mt.2016.143

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  196 in total

1.  High fidelity of yellow fever virus RNA polymerase.

Authors:  Konstantin V Pugachev; Farshad Guirakhoo; Simeon W Ocran; Fred Mitchell; Megan Parsons; Caroline Penal; Soheila Girakhoo; Svetlana O Pougatcheva; Juan Arroyo; Dennis W Trent; Thomas P Monath
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 2.  Messenger RNA decay in mammalian cells: the exonuclease perspective.

Authors:  David T Fritz; Naomi Bergman; Walter J Kilpatrick; Carol J Wilusz; Jeffrey Wilusz
Journal:  Cell Biochem Biophys       Date:  2004       Impact factor: 2.194

3.  Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection.

Authors:  Zeyu Xiao; Etgar Levy-Nissenbaum; Frank Alexis; Andrej Lupták; Benjamin A Teply; Juliana M Chan; Jinjun Shi; Elise Digga; Judy Cheng; Robert Langer; Omid C Farokhzad
Journal:  ACS Nano       Date:  2012-01-03       Impact factor: 15.881

4.  3'-end labeling of RNA with recombinant yeast poly(A) polymerase.

Authors:  J Lingner; W Keller
Journal:  Nucleic Acids Res       Date:  1993-06-25       Impact factor: 16.971

5.  A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.

Authors:  Susan F Slovin; Marissa Kehoe; Robert Durso; Celina Fernandez; William Olson; Jian P Gao; Robert Israel; Howard I Scher; Stephen Morris
Journal:  Vaccine       Date:  2012-12-13       Impact factor: 3.641

6.  Newly-developed Sendai virus vector for retinal gene transfer: reduction of innate immune response via deletion of all envelope-related genes.

Authors:  Yusuke Murakami; Yasuhiro Ikeda; Yoshikazu Yonemitsu; Sakura Tanaka; Haruhiko Kondo; Shinji Okano; Ri-Ichiro Kohno; Masanori Miyazaki; Makoto Inoue; Mamoru Hasegawa; Tatsuro Ishibashi; Katsuo Sueishi
Journal:  J Gene Med       Date:  2008-02       Impact factor: 4.565

7.  Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors.

Authors:  N L Paul; M Marsh; J A McKeating; T F Schulz; P Liljeström; H Garoff; R A Weiss
Journal:  AIDS Res Hum Retroviruses       Date:  1993-10       Impact factor: 2.205

8.  Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus.

Authors:  M J Ensinger; S A Martin; E Paoletti; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1975-07       Impact factor: 11.205

Review 9.  HIV-1 RNA dimerization: It takes two to tango.

Authors:  Michael D Moore; Wei Shau Hu
Journal:  AIDS Rev       Date:  2009 Apr-Jun       Impact factor: 2.500

10.  Nuclear reprogramming with a non-integrating human RNA virus.

Authors:  Christopher B Driscoll; Jason M Tonne; Moustafa El Khatib; Roberto Cattaneo; Yasuhiro Ikeda; Patricia Devaux
Journal:  Stem Cell Res Ther       Date:  2015-03-26       Impact factor: 6.832

View more
  20 in total

1.  Biomedical Applications of RNA-Based Devices.

Authors:  Cameron M Kim; Christina D Smolke
Journal:  Curr Opin Biomed Eng       Date:  2017-10-18

Review 2.  Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations.

Authors:  Isabella Hetherington; Hana Totary-Jain
Journal:  Mol Ther       Date:  2022-09-05       Impact factor: 12.910

3.  A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Authors:  Jesse H Erasmus; Amit P Khandhar; Jeff Guderian; Brian Granger; Jacob Archer; Michelle Archer; Emily Gage; Jasmine Fuerte-Stone; Elise Larson; Susan Lin; Ryan Kramer; Rhea N Coler; Christopher B Fox; Dan T Stinchcomb; Steven G Reed; Neal Van Hoeven
Journal:  Mol Ther       Date:  2018-08-02       Impact factor: 11.454

4.  M3RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction.

Authors:  Raman Deep Singh; Matthew L Hillestad; Christopher Livia; Mark Li; Alexey E Alekseev; Tyra A Witt; Paul G Stalboerger; Satsuki Yamada; Andre Terzic; Atta Behfar
Journal:  Tissue Eng Part A       Date:  2018-09-21       Impact factor: 3.845

5.  Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs.

Authors:  Zifu Zhong; Séan McCafferty; Lisa Opsomer; Haixiu Wang; Hanne Huysmans; Joyca De Temmerman; Stefan Lienenklaus; João Paulo Portela Catani; Francis Combes; Niek N Sanders
Journal:  Mol Ther       Date:  2021-01-21       Impact factor: 11.454

6.  Comparison of the cellular transport mechanism of cationic, star-shaped polymers and liposomes in HaCat cells.

Authors:  Heng-Cong Luo; Na Li; Li Yan; Kai-Jin Mai; Kan Sun; Wei Wang; Guo-Juan Lao; Chuan Yang; Li-Ming Zhang; Meng Ren
Journal:  Int J Nanomedicine       Date:  2017-02-07

7.  Investigating Tick-borne Flaviviral-like Particles as a Delivery System for Gene Therapy.

Authors:  Anne H Neddermeyer; Kjell Hultenby; Maruthibabu Paidikondala; Ryan M Schuchman; Mehdi R M Bidokhti
Journal:  Curr Ther Res Clin Exp       Date:  2017-10-16

Review 8.  Controlling timing and location in vaccines.

Authors:  Darrell J Irvine; Aereas Aung; Murillo Silva
Journal:  Adv Drug Deliv Rev       Date:  2020-06-26       Impact factor: 15.470

9.  Evaluation of modified Interferon alpha mRNA constructs for the treatment of non-melanoma skin cancer.

Authors:  Sarah Hochmann; Michaela Mittermeir; Radmila Santic; Frieder Koszik; Lanay Griessner; Alina Sarah Sonderegger; Thomas Hoffmann; Elisabeth Russe; Sandra Scheiblhofer; Richard Weiss; Markus Mandler; Achim Schneeberger; Dirk Strunk
Journal:  Sci Rep       Date:  2018-08-28       Impact factor: 4.379

Review 10.  From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Sang-Soo Lee
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.